company background image

Dar Al-Shifa Pharmaceuticals PLSE:PHARMACARE Stock Report

Last Price


Market Cap







27 Sep, 2022


Company Financials
PHARMACARE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance5/6
Financial Health4/6

PHARMACARE Stock Overview

Dar Al-Shifa Pharmaceuticals Company imports, manufactures, sells, distributes, and exports medicines, cosmetics, chemicals, and biocides in West Bank and Gaza Strip.

Dar Al-Shifa Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dar Al-Shifa Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.12
52 Week HighUS$3.40
52 Week LowUS$3.11
1 Month Change0%
3 Month Changen/a
1 Year Change-8.24%
3 Year Change-13.33%
5 Year Change-13.33%
Change since IPO-30.67%

Recent News & Updates

Shareholder Returns

PHARMACAREPS PharmaceuticalsPS Market

Return vs Industry: PHARMACARE exceeded the PS Pharmaceuticals industry which returned -19.9% over the past year.

Return vs Market: PHARMACARE underperformed the PS Market which returned 8.4% over the past year.

Price Volatility

Is PHARMACARE's price volatile compared to industry and market?
PHARMACARE volatility
PHARMACARE Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement4.8%
Market Average Movement2.8%
10% most volatile stocks in PS Market5.6%
10% least volatile stocks in PS Market1.3%

Stable Share Price: Insufficient data to determine PHARMACARE's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine PHARMACARE's volatility change over the past year.

About the Company

1986423Bassim Subhi Farah Nasr

Dar Al-Shifa Pharmaceuticals Company imports, manufactures, sells, distributes, and exports medicines, cosmetics, chemicals, and biocides in West Bank and Gaza Strip. The company offers various human medicines, such as grains, capsules, creams, and fluids, as well as veterinary treatment products. Dar Al-Shifa Pharmaceuticals Company was founded in 1986 and is headquartered in Ramallah, the Palestinian Authority.

Dar Al-Shifa Pharmaceuticals Fundamentals Summary

How do Dar Al-Shifa Pharmaceuticals's earnings and revenue compare to its market cap?
PHARMACARE fundamental statistics
Market CapUS$26.81m
Earnings (TTM)US$4.87m
Revenue (TTM)US$30.71m


P/E Ratio


P/S Ratio

Is PHARMACARE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHARMACARE income statement (TTM)
Cost of RevenueUS$17.62m
Gross ProfitUS$13.09m
Other ExpensesUS$8.23m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)0.57
Gross Margin42.63%
Net Profit Margin15.85%
Debt/Equity Ratio74.0%

How did PHARMACARE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is PHARMACARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHARMACARE?

Other financial metrics that can be useful for relative valuation.

PHARMACARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA5.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does PHARMACARE's PE Ratio compare to its peers?

PHARMACARE PE Ratio vs Peers
The above table shows the PE ratio for PHARMACARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average10.5x
BJP Beit Jala Pharmaceutical
JPH Jerusalem Pharmaceuticals
BPC Birzeit Pharmaceuticals
500009 Ambalal Sarabhai Enterprises
PHARMACARE Dar Al-Shifa Pharmaceuticals

Price-To-Earnings vs Peers: PHARMACARE is good value based on its Price-To-Earnings Ratio (5.5x) compared to the peer average (10.5x).

Price to Earnings Ratio vs Industry

How does PHARMACARE's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PHARMACARE is good value based on its Price-To-Earnings Ratio (5.5x) compared to the Asian Pharmaceuticals industry average (21.4x)

Price to Earnings Ratio vs Fair Ratio

What is PHARMACARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHARMACARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHARMACARE's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PHARMACARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHARMACARE ($3.12) is trading below our estimate of fair value ($5.54)

Significantly Below Fair Value: PHARMACARE is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Dar Al-Shifa Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dar Al-Shifa Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether Dar Al-Shifa Pharmaceuticals is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Dar Al-Shifa Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHARMACARE has high quality earnings.

Growing Profit Margin: PHARMACARE's current net profit margins (15.8%) are higher than last year (11.3%).

Past Earnings Growth Analysis

Earnings Trend: PHARMACARE's earnings have grown by 19.4% per year over the past 5 years.

Accelerating Growth: PHARMACARE's earnings growth over the past year (86.9%) exceeds its 5-year average (19.4% per year).

Earnings vs Industry: PHARMACARE earnings growth over the past year (86.9%) exceeded the Pharmaceuticals industry 6%.

Return on Equity

High ROE: PHARMACARE's Return on Equity (17.9%) is considered low.

Discover strong past performing companies

Financial Health

How is Dar Al-Shifa Pharmaceuticals's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PHARMACARE's short term assets ($29.7M) exceed its short term liabilities ($21.2M).

Long Term Liabilities: PHARMACARE's short term assets ($29.7M) exceed its long term liabilities ($23.9M).

Debt to Equity History and Analysis

Debt Level: PHARMACARE's net debt to equity ratio (70.5%) is considered high.

Reducing Debt: PHARMACARE's debt to equity ratio has increased from 58.1% to 74% over the past 5 years.

Debt Coverage: PHARMACARE's debt is well covered by operating cash flow (41.8%).

Interest Coverage: PHARMACARE's interest payments on its debt are well covered by EBIT (5.4x coverage).

Balance Sheet

Discover healthy companies


What is Dar Al-Shifa Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Dar Al-Shifa Pharmaceuticals Dividend Yield vs Market
How does Dar Al-Shifa Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Dar Al-Shifa Pharmaceuticals)3.2%
Market Bottom 25% (PS)2.8%
Market Top 25% (PS)5.2%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast in 3 Years (Dar Al-Shifa Pharmaceuticals)n/a

Notable Dividend: PHARMACARE's dividend (3.21%) is higher than the bottom 25% of dividend payers in the PS market (2.78%).

High Dividend: PHARMACARE's dividend (3.21%) is low compared to the top 25% of dividend payers in the PS market (5.15%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PHARMACARE has been paying a dividend for less than 10 years.

Growing Dividend: PHARMACARE's dividend payments have increased, but the company has only paid a dividend for 7 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (17.7%), PHARMACARE's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (22.7%), PHARMACARE's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Bassim Subhi Farah Nasr

no data


Mr. Bassim Subhi Farah Khoury Nasr serves as Executive Chairman, Chief Executive Officer and General Manager at Dar Al-Shifa Pharmaceuticals Company (formerly known as Dar Al-Shifa'a for the Manufacturing...


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHARMACARE?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Dar Al-Shifa Pharmaceuticals Company's employee growth, exchange listings and data sources

Key Information

  • Name: Dar Al-Shifa Pharmaceuticals Company
  • Ticker: PHARMACARE
  • Exchange: PLSE
  • Founded: 1986
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$26.813m
  • Shares outstanding: 8.59m
  • Website:

Number of Employees


  • Dar Al-Shifa Pharmaceuticals Company
  • Industrial Area
  • Embassy road
  • Ramallah
  • Palestinian Authority


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHARMACAREPLSE (Palestine Securities Exchange)YesOrdinary SharesPSUSDJun 2013

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/08/10 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.